Ras association domain family member 9Genealiases: P-CIP1 · PAMCI · PCIP1
Q-omics provides the consensus-scored RASSF9 profile across patient tissues and cancer cell-line models. RASSF9 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RASSF9 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RASSF9 RNA expression shows 17,793 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where RASSF9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASSF9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASSF9 survival associations across molecular data types. RASSF9 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASSF9 RNA expression–survival associations across cancer types. High RASSF9 expression shows unfavorable associations in BLCA, KIRP and UCEC, but favorable associations in KIRC, HNSC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RASSF9 RNA expression.
This table summarizes RASSF9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RASSF9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASSF9 shows lower tumor expression in KIRC, THCA, KICH, KIRP, LUAD and UCEC. The KIRC box plot shows higher RASSF9 RNA expression in normal versus tumor tissue (log2 FC = −1.513, t-test p < 0.001).
This table shows molecular features associated with RASSF9 in patient tissues and cancer cell lines. In patient samples, RASSF9 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RASSF9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
